Valuation: Synovics Pharmaceuticals, Inc.

Market Cap 16.41L 14.4L 13.41L 12.33L 23.12L 16Cr 23.51L 1.59Cr 62.26L 7.77Cr 61.59L 60.26L 27Cr P/E 2007
-0.73x
P/E 2008 -2.06x
Enterprise Value 81.29L 71.34L 66.43L 61.1L 1.15Cr 78Cr 1.17Cr 7.88Cr 3.08Cr 39Cr 3.05Cr 2.99Cr 133.07Cr EV / Sales 2007
1.81x
EV / Sales 2008 0.6x
Free-Float
95.75%
Yield 2007 *
-
Yield 2008 -
Current year 0
Extreme 0
0
1 year 0
Extreme 0
0
3 years 0
Extreme 0
0
5 years 0
Extreme 0
0
10 years 0
Extreme 0
0
Change 5-day change 1-year change 3-year change Capi.($)
-50.00%-.--%-.--%-.--% 3.65T
+1.94%+3.85%+51.05%+166.24% 1,06800Cr
+0.42%+6.66%+60.82%+53.20% 64TCr
+3.30%+3.44%+40.53%+75.62% 45TCr
+2.17%+10.22%+41.17%+36.56% 35TCr
+1.46%+3.87%+39.70%+44.49% 30TCr
+0.40%+3.59%+19.93%+17.02% 27TCr
+2.73%+3.50%-25.66%-36.53% 22TCr
+4.08%+6.71%+29.72%+65.35% 20TCr
+2.59%+2.67%+18.34%+74.03% 16TCr
Average -3.05%+2.48%+27.56%+49.60% 36.63TCr
Weighted average by Cap. +1.94%+2.85%+40.09%+80.21%

Financials

2007 2008
Net sales 2.35Cr 2.06Cr 1.92Cr 1.76Cr 3.31Cr 224.19Cr 3.36Cr 23Cr 8.91Cr 111.18Cr 8.81Cr 8.62Cr 384.14Cr 2.6Cr 2.28Cr 2.12Cr 1.95Cr 3.66Cr 248.01Cr 3.72Cr 25Cr 9.85Cr 123Cr 9.75Cr 9.54Cr 424.95Cr
Net income -2.09Cr -1.83Cr -1.7Cr -1.57Cr -2.94Cr -199.27Cr -2.99Cr -20Cr -7.92Cr -99Cr -7.83Cr -7.66Cr -341.44Cr -40.06L -35.16L -32.74L -30.11L -56.44L -38Cr -57.41L -3.88Cr -1.52Cr -19Cr -1.5Cr -1.47Cr -66Cr
Net Debt 1.88Cr 1.65Cr 1.54Cr 1.41Cr 2.65Cr 179.51Cr 2.69Cr 18Cr 7.13Cr 89Cr 7.05Cr 6.9Cr 307.59Cr 64.88L 56.94L 53.02L 48.77L 91.42L 62Cr 92.99L 6.29Cr 2.46Cr 31Cr 2.44Cr 2.38Cr 106.21Cr
Logo Synovics Pharmaceuticals, Inc.
Synovics Pharmaceuticals, Inc. (Synovics) is a specialty pharmaceutical company engaged in the development, manufacturing and commercialization of generic over the counter (OTC) pharmaceutical products and generic prescription drug products. The Company is a manufacturer, packager and distributor of private label, or store brand, OTC products to chain drug stores, wholesalers and distributors throughout the United States. The Company’s OTC product categories include analgesics, cough and cold, antihistamines, asthma relief and laxatives. The Company has two primary subsidiaries, Kirk Pharmaceuticals, LLC (Kirk), and ANDAPharm, LLC (ANDAPharm). Kirk manufactures and distributes OTC products developed by or licensed to the Company. ANDAPharm serves as the product research and RX manufacturing arm of the Company with a focus on the development of active compounds for drugs.
Employees
155
  1. Stock Market
  2. Stocks
  3. SYVC Stock